New updates have been reported about Levee Medical.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Levee Medical has closed an oversubscribed funding round of more than $12 million, completed ahead of plan, extending its cash runway to support the premarket approval process for its Voro® Urologic Scaffold following completion of enrollment in the ARID II pivotal trial. CEO Adam Irving said the additional capital positions the company to stay focused on delivering robust clinical results that matter to both patients and stakeholders as it advances through the PMA pathway.
The ARID II study, a multicenter randomized trial in men undergoing robotic-assisted radical prostatectomy, is evaluating the safety and effectiveness of the scaffold, with 40 surgeons now participating under the leadership of principal investigator Dr. Scott Eggener of UCLA. Clinical leaders involved in the trial emphasized standardizing an evidence-based, reproducible implant technique and highlighted the device’s potential to reduce early stress urinary incontinence and speed recovery, as Levee Medical continues disciplined execution toward a future PMA submission and potential first commercial product launch.